Tuesday, December 3, 2024

SCOTUS appears to lean toward FDA in e-cig case

Presented by Blue Cross Blue Shield Association: Delivered every Tuesday and Friday by 12 p.m., Prescription Pulse examines the latest pharmaceutical news and policy.
Dec 03, 2024 View in browser
 
POLITICO Prescription Pulse Newsletter Header

By David Lim and Lauren Gardner

Presented by Blue Cross Blue Shield Association

Driving the day

People walk by the Supreme Court building.

Tourists gather at the Supreme Court, which on Monday heard oral arguments on a case about the FDA's rejection of vaping product applications. | Chip Somodevilla/Getty Images

FDA’S DAY AT SCOTUS — Don’t expect the Supreme Court to take a sledgehammer to the FDA’s ability to regulate tobacco.

The high court heard oral arguments on Monday from Texas-based Triton Distribution, which asked the court to affirm a lower court’s ruling that the agency reconsider its applications to sell flavored liquids containing nicotine that e-cigarettes heat for a user to inhale.

Triton and a partner e-cigarette product maker, Vapetasia, also argued that the FDA was not consistent about the type of data it needed to support approval of the products.

But several justices did not seem convinced by the company’s lawyer — instead appearing inclined to support the agency. Liberal justices repeatedly seemed to back the FDA’s stance that the underlying law backs its actions to deny e-cigarette products.

“Everybody basically knows that flavors are particularly dangerous in terms of kids starting the use of smoking products,” Justice Elena Kagan said.

And a handful of conservatives questioned if there is a remedy that would have a practical impact.

“I'm curious what relief looks like in this case, because the companies can always reapply,” Justice Brett Kavanaugh said.

Timing: A decision is expected by the end of the Supreme Court term in June, but the FDA could potentially change its regulatory approach to e-cigarettes even in absence of a ruling favorable to the industry. President-elect Donald Trump pledged to “save” vaping on his Truth Social site in September.

William Schultz, an attorney at Zuckerman Spaeder who was HHS general counsel under former President Barack Obama, said it is always hard to predict how the court will rule. But he noted the conservative justices were not hostile to the position the government took during the oral arguments.

“It’s a new program, and you're going to expect the agency on product approvals to learn and kind of incorporate what it learned as it does the reviews,” said Schultz, who is a consultant to the Campaign for Tobacco-Free Kids, an advocacy group that wants to ban flavored tobacco products.

Curtis Gannon, the Justice Department deputy solicitor general defending the FDA, argued that the agency could have simply given no guidance and just relied on the underlying statute when issuing authorizing decisions. But many industries regulated by the FDA welcome the recommendations from the agency because they lend transparency into its thinking.

IT’S TUESDAY. WELCOME BACK TO PRESCRIPTION PULSE. If you work in the Senate and see that your boss has a meeting lined up with any of the president-elect’s health agency picks, do let your morning hosts know!

Send tips to David Lim (dlim@politico.com or @davidalim) and Lauren Gardner (lgardner@politico.com or @Gardner_LM).

 

A message from Blue Cross Blue Shield Association:

Corporate hospital systems are driving up the cost of care for common medical procedures by buying up independent doctors’ offices and tacking on unnecessary fees. Consumers’ bills can be as much as four times higher even though it is often the same service, from the same doctor, in the same location. Congress can fix it—and save taxpayers billions. See solutions to end dishonest hospital billing and make health care more affordable for everyone.

 
In Congress

CRITIQUES AND LAB LEAKS — The Republican leader of the House panel formed to investigate the Covid-19 pandemic released a report Monday criticizing federal health agencies’ response and reiterated many GOP lawmakers’ views that the virus originated from a lab leak, POLITICO’s Robert King reports.

The Select Subcommittee on the Coronavirus Pandemic will vote on approving the 520-page report Wednesday.

The report finds that the system for compensating people who experience serious side effects after vaccination is broken — a complaint shared by those who study vaccine safety and represent the vaccine-injured in the legal system. But it also focuses on 1.8 million adverse events from Covid vaccines reported by the public, a raw number that doesn’t offer details about the severity of each instance, much less whether it was causally linked to the shot.

The report also embraces arguments that the virus emerged from a Chinese lab studying coronaviruses. Many public health experts maintain the virus naturally spilled over into humans from an animal host, but the U.S. intelligence community is divided on the likeliest origin absent more information from China.

Related: Our POLITICO colleagues examined how the critiques leveled by “Covid contrarians” set to take on leadership roles in the next Trump administration have aged.

Scott Gottlieb is pictured.

Former FDA Commissioner Scott Gottlieb is warning senators that the confirmation of Robert Kennedy Jr. to head HHS could be dangerous. | Drew Angerer/Getty Images

GOTTLIEB VS. KENNEDY — The prospect of Robert F. Kennedy Jr. leading HHS has led former FDA Commissioner Scott Gottlieb to warn senators that his confirmation could cost lives due to lower childhood vaccination rates.

“I think that there’s skepticism in the Republican caucus, more than the press is reporting right now,” Gottlieb recently said on CNBC’s “Squawk Box," noting that he’s raised his concerns to individual senators. Congressional attempts to put guardrails on Kennedy via the appropriations process are “not going to be successful,” he added, all but suggesting the only way to rein him in would be to reject his confirmation.

Meanwhile, Gottlieb had high praise for pancreas surgeon Dr. Marty Makary, Trump’s pick to lead the FDA: “He’s a good physician and a really good thinker.”

BIRD FLU


TWO MORE HUMAN CASES — The California Department of Public Health on Monday announced two more confirmed human avian flu cases — bringing the total in the state this year to 31.

The department maintains the risk to the public remains low and that no human-to-human spread of the disease has been documented in the state.

 

A message from Blue Cross Blue Shield Association:

Advertisement Image

 
Industry Intel

Novartis said Monday it struck a $1 billion licensing and collaboration deal with PTC Therapeutics for a potential Huntington’s disease therapy.

The candidate would be the first oral disease-modifying drug for the neurodegenerative disease if approved. Novartis will take over development, manufacturing and commercialization once PTC finishes its ongoing Phase II trial, likely in the first half of 2025.

Document Drawer

The FDA has reopened the public comment period on its Oct. 21 joint meeting with the National Institutes of Health on promoting smoking cessation, taking submissions until Dec. 20.

WHAT WE'RE READING

POLITICO’s Robert King spoke to former CMS Administrator Donald Berwick about Dr. Mehmet Oz’s selection to lead the agency during the second Trump administration, and what awaits him there.

The New York Times profiled Dr. Dave Weldon, a former Republican congressmember from Florida who’s espoused some vaccine-skeptical views and who’s Trump’s pick to lead the CDC.

Workers at a California lab helping respond to the avian flu outbreak among cattle and poultry say they are overworked and understaffed, the Los Angeles Times’ Suhauna Hussain reports.

 

A message from Blue Cross Blue Shield Association:

Americans deserve lower health care costs—Congress can help. Costs for outpatient care have increased substantially, fueled in part by the growing trend of corporate health systems acquiring small, independent physician practices. With a simple name change, they can increase prices without improving the quality of care or improving patient outcomes. These price increases mean higher premiums and out-of-pocket costs, putting care out of reach for some American families.

To make hospital billing more fair and reasonable for patients, policymakers can support site-neutral payments and ensure the cost for a health care procedure is the same regardless of where the procedure takes place.

Learn how Blue Cross and Blue Shield companies are working to enact commonsense policy solutions to make health care more affordable for all Americans.

 
 

Follow us on Twitter

David Lim @davidalim

Lauren Gardner @Gardner_LM

 

Follow us

Follow us on Facebook Follow us on Twitter Follow us on Instagram Listen on Apple Podcast
 

To change your alert settings, please log in at https://login.politico.com/?redirect=https%3A%2F%2Fwww.politico.com/settings

This email was sent to edwardlorilla1986.paxforex@blogger.com by: POLITICO, LLC 1000 Wilson Blvd. Arlington, VA, 22209, USA

Unsubscribe | Privacy Policy | Terms of Service

No comments:

Post a Comment

MTA Live - December 4th 2024

Join Nate Bear during his LIVE Sector Strike Mission Briefing on Wednesday, December 4th @ 2PM! ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌...